Skip to ContentSkip to Navigation
Practical matters How to find us prof. dr. H.J. (Hiddo) Lambers Heerspink


Albuminuria as a marker of systemic congestion in patients with heart failure( )

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)

Development and Validation of a Prediction Model for Future Estimated Glomerular Filtration Rate in People With Type 2 Diabetes and Chronic Kidney Disease

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes

Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [18F]Canagliflozin in Patients with Type 2 Diabetes

Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

Read more


Diabetes drug can slow kidney function decline, study finds

La dapagliflozina no reduce los riesgos en los pacientes hospitalizados con COVID-19

Dapagliflozin did not reduce risks in patients hospitalized with COVID-19

Does the Drug Dapagliflozin Benefit Hospitalized Patients with Covid-19?

SGLT2 Inhibitor Safe for Kidneys in Hospitalized COVID Patients

Screening for Albuminuria at the First Line for Early Identification of CKD (SALINE)

Ontwikkelingen in de behandeling van patiënten met diabetische nierziekte

Review of the 57th Annual European Association for the Study of Diabetes (EASD) Congress

Read more